AKT1 and non-small cell lung carcinoma: Several groups are studying the modulation of the PI3K/AKT pathway as a promising strategy to overcome resistance to EGFR pathway-based therapies in NSCLC, considering the several shared downstream effectors common to the two signaling networks.